New technologies are transforming early ovarian cancer detection, aiming to identify this “silent killer” at more treatable stages. AI-powered tools like Ovatools combine biomarkers such as CA125 with patient data to generate personalized risk scores, improving early diagnosis. Machine learning is also being used to analyze metabolic patterns in blood, detecting subtle cancer signals with greater precision than traditional tests.
Liquid biopsies offer a non-invasive breakthrough by detecting circulating tumor DNA and DNA methylation patterns from a simple blood draw. Emerging tests using multiple DNA biomarkers can identify major ovarian cancer types with high accuracy. At the same time, nanotechnology approaches—such as nanopore sensing with gold nanoparticles—can detect cancer-related peptides in urine, offering a convenient and accessible screening method.
Advanced imaging is also evolving. New endoscopic probes integrate optical coherence tomography, photoacoustic imaging, and ultrasound into one device, providing detailed, real-time visualization. Together, these innovations promise earlier, more accurate, and less invasive ovarian cancer diagnosis.